Supplements can reduce inflammation and boost longevity. Here's what one cardiologist takes to lower his risk of heart disease.
You can sign up for Business Insider's daily newsletter here.
Welcome back! Apparently, there's a hot new summer cocktail, and it's called the Hugo Spritz. Find out why everyone is jumping on this bubbly's bandwagon.
On the agenda:
Frequent-flying elites told BI their tips to overcome jet lag.
Wall Street's biggest summer status symbol isn't a house in the Hamptons. It's a golf shirt.
BI's Kim Schewitz took a class to boost her VO2 max — and finally made cardio fun.
Avoid making these mistakes if you find yourself staying in a five-star hotel.
But first: Let's talk about matters of the heart.
If this was forwarded to you, sign up here. Download Business Insider's app here.
This week's dispatch
And the (heart)beat goes on…
We know supplements can reduce inflammation, boost strength training, and strengthen your immune system. But did you also know that the right stack can also protect you from heart failure?
Dr. Dmitry Yaranov, the director of the advanced heart failure program at Baptist Memorial Hospital in Memphis, Tennessee, told BI senior reporter Julia Pugachevsky that he takes three supplements to reduce his risk.
Here's what's in his medicine cabinet:
Omega-3: Yaranov said he takes this supplement because he's "not getting enough fresh, fatty fish in my diet." Pugachevsky notes that taking omega-3 "helps to support healthy blood cells, reducing the risk of blood clots" and can reduce the risk of strokes and heart attacks.
Magnesium: Pugachevsky said that this supplement, typically found in black beans and spinach, "supports heart, bone, brain, and muscle health" and helps with controlling blood pressure.
Vitamin D: Yaranov said he spends "a long time indoors," which contributes to his lower levels of this essential vitamin, so he started supplementing it. Research shows that Vitamin D is also associated with a lower risk of heart disease in adults over the age of 60.
Skip the jet lag
Jet lag, which can cause brain fog, fatigue, and digestive issues, could derail your entire travel experience. It happens when your local time zone is misaligned with your internal clocks.
People who fly regularly — from pro athletes to CEOs — told BI how they beat jet lag, including the supplements they take and the adjustments they make before traveling.
From diet changes to light therapy.
The ultimate finance bro flex
In the realm of posh sports, not much ranks higher than golf, and its elitist nature often manifests in fashion. Donning a logoed golf polo from the course you play has become a subtle status symbol among Wall Street golf bros.
Many men described the logoed gear to BI's Emily Stewart as a "head nod," but there's a hierarchy associated with it, too. Just don't get caught wearing a golf polo from a course you've never played.
If you know, you know.
Also read:
Gen Z is storming the links
A class dedicated to boosting your VO2 max
VO2 max has become the latest fitness craze that measures cardiovascular fitness among runners, fitness competition bros, and more. People are obsessed with the metric because it's said to be a strong predictor of longevity. A high VO2 max is also linked to a longer life and a reduced risk of certain health conditions.
So when London's GymBox came out with a new VO2:MAXED cardio class, BI's Kim Schewitz, who said she doesn't do cardio, tried it out. She found out her VO2 score was low.
But it made cardio fun for her.
Five-star faux pas
BI's travel reporter Joey Hadden has stayed at 10 five-star hotels across the Americas and Europe. She shared six mistakes she's made during these swanky stays, so you won't have to.
For instance, Hadden learned you should always pack a swimsuit, but you won't need to bring toiletries. Plus, turndown service is a must — you never know what treats you'll get.
She recommends booking more than one night.
What we're watching this weekend
"Miley Cyrus: Something Beautiful": The chart-topping artist turned her 2025 album of the same name into a stunning visual companion that's now available on Disney+ and Hulu.
"The Amateur": Now on Hulu, this thriller stars Rami Malek as a CIA decoder who is out for vengeance after the death of his wife. Rachel Brosnahan, Laurence Fishburne, and Jon Bernthal also star.
"Billy Joel: And So It Goes": This two-part documentary on HBO Max looks at the legendary life and career of The Piano Man, Billy Joel.
What to shop
TV on wheels: This touchscreen on wheels is like a smart‑TV‑tablet hybrid that lets you stream or scroll wherever you roll it. Its portable convenience makes it a delightful, lifestyle‑first gadget that editor Sam Crozier loves for her small Brooklyn apartment.
A shirt to do it all: Public Rec's Go‑To Polo is crafted with a cooling, stretchy cotton‑blend that is so comfortable our men's style editor, Amir Ismael, swears you can work out in it. Here's why we recommend it for your closet.
A heated hand massager: Social media fiends, rock climbers, and desk jockeys with carpal tunnel all have one thing in common: they need a hand massage. This handy device isn't a cure-all, but its gentle heat and snug fit make it a great self-care accessory that senior associate editor Gabrielle Chase swears by.
More of this week's top reads:
A doctor who studies how a healthy gut can prevent colon cancer does three simple things to lower his risk.
Interior designers share the nine trends they wish they saw more of in homes.
Six purses to buy if you don't want to carry the same luxury bag everyone else has.
I opened a mobile coffee bar for $10,000. My schedule is flexible and I can make thousands working 30-hour weeks.
NFL quarterback Josh Allen says he's cutting out these two foods — and his diet is 'probably the best it's ever been.'
I booked basic economy flights with Delta and Alaska Airlines. One was clearly better for coach passengers.
A Microsoft engineer turned health tech CEO spends $24,000 a year on his health, including $15,000 on a solo Bali trip.
I moved to Denver to be with my husband. We're still together, but I'm returning to New York City alone.
Fitness Money Diaries: How a Microsoft engineer turned health tech CEO spends $24,000 a year on wellness.
The BI Today team: Lisa Ryan, executive editor, in New York. Akin Oyedele, deputy editor, in New York. Grace Lett, editor, in New York. Amanda Yen, associate editor, in New York.
Read the original article on Business Insider
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
26 minutes ago
- Yahoo
BD Announces First Pharma-Sponsored Clinical Trial Using BD Libertas™ Wearable Injector Technology for Biologic Drugs
FRANKLIN LAKES, N.J., July 23, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announces the first pharma-sponsored combination product clinical trial using the BD Libertas™ Wearable Injector for subcutaneous delivery of complex biologics. The selection of BD Libertas™ Wearable Injector for this pharma-sponsored trial follows successful outcomes from more than 50 BD-conducted pre-clinical and clinical studies, including a device clinical study demonstrating excellent performance with 100% of study participants stating they would likely use the BD Libertas™ Wearable Injector if prescribedi,ii. The pharma-sponsored combination product clinical trial represents a significant advancement in accelerating innovation in drug-device combination products that provide greater flexibility for patients, including potential conversion from infused medications that require patients to travel to a hospital or clinic to more convenient patient care in various settings, including self-injection at home. "This trial demonstrates BD's commitment to helping pharma companies by advancing large-volume injection science, ensuring therapies are accessible and patient friendly by offering more efficient and convenient options for biologics," said Patrick Jeukenne, worldwide president of BD Pharmaceutical Systems. "BD's enhanced testing capabilities acquired through ZebraSci and the proven capabilities of the BD Libertas™ Wearable Injector technology further position BD as an innovative leader in drug delivery." The BD Libertas™ Wearable Injector is an innovative, prefilled, patient ready-to-use drug delivery systemiii designed to enable delivery of complex biologics via subcutaneous injection. The biologics market is expected to grow to more than $670 billioniv by 2030 and for pharmaceutical companies developing these complex drugs, the BD Libertas™ Wearable Injector offers a customizable, patient-centric solution. The BD Libertas™ Wearable Injector: Supports delivery of high-viscosity biologics (up to 50 centipoise), enabling a wide range of subcutaneous therapies Is offered in 2 to 5 mL and 5 to 10 mL configurations providing flexibility for diverse therapeutic requirements Features a fully mechanical, patient ready-to-use design with a simple "peel, stick and click" mechanism, requiring no end-user filling or assemblyiii BD's ongoing validations of fill-finish and final assembly processes with multiple Contract Manufacturing Organizations (CMOs) enable the company to support pharmaceutical partners from development through commercial-scale production. For more information about how BD Libertas™ Wearable Injector is enabling biologic therapy delivery, visit About BD Libertas™ Wearable InjectorBD Libertas™ Wearable Injector is a product in development; some statements are forward looking and are subject to a variety of risks and uncertainties. BD Libertas™ Wearable Injector is a device component intended for drug-device combination products and not subject to FDA 510(k) clearance or separate EU CE mark certification. About BD BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit or connect with us on LinkedIn at X (formerly Twitter) @BDandCo or Instagram @becton_dickinson. Contacts: Media: Investors: Fallon McLoughlin Adam Reiffe BD Corporate Communications BD Investor Relations 201.258.0361 201.847.6927 i Early feasibility clinical study of investigational BD Libertas™ Wearable Injector (WI) evaluated 5ml, non- Newtonian ~8cP subcutaneous placebo injections in 52 healthy adult subjects for functionality, tissue effects, subject tolerability (100mm Visual Analog Scale (VAS)) and acceptability (questionnaires with 5-point Likert or yes /no responses). Tissue effects were measured from WI removal post-injection through 24 hours with calipers (wheals) or graded on a 5-point scale (erythema, bleeding) from 0-none to 4-severe, significant, respectively. Where tissue effects were observed, the majority (>50%) were resolved within 60 minutes and all within 24 hours. Subject pain (100mm VAS) peaked mid-injection (mean 9.1mm, SD 13.4) and rapidly resolved within 30 minutes (mean 0 .4mm, SD 2.6). Subjects found acceptable (Likert agree + strongly agree or yes responses) their peak pain (≥90.2%), injection site appearance (≥92.2% ).ii Woodley, W. D. et al. Clinical Evaluation of an Investigational 5ml Wearable Injector in Healthy Human Subjects. Clin Transl Sci. 2021 May;14(3):859-869. Pharma filled and assemblediv Mordor Intelligence (2025). Biologics Market Size - Industry Report on Share, Growth Trends & Forecasts Analysis (2025 - 2030). View original content to download multimedia: SOURCE BD (Becton, Dickinson and Company) Sign in to access your portfolio
Yahoo
26 minutes ago
- Yahoo
U.S. Physical Therapy, Inc. Schedules Second Quarter 2025 Earnings Release and Conference Call Dates
HOUSTON, July 23, 2025--(BUSINESS WIRE)--U.S. Physical Therapy, Inc. (NYSE: USPH), a national operator of outpatient physical therapy clinics and provider of industrial injury prevention services, announced that it will report its financial results for the three months and six months ended June 30, 2025, on Wednesday, August 6, 2025, after the stock market closes, with the conference call to follow the next morning, on Thursday, August 7, 2025. Conference Call Date: Thursday, August 7, 2025 Time: 10:30 am Eastern / 9:30 am Central Dial-In Number: (800) 343-4136 Primary or (203) 518-9843 Alternate Conference ID: USPHQ225 (In order to join this conference call,you will be required to provide the Conference ID listed above) To participate, please call in 15 minutes prior to start time. To listen to the live call, please go to and click on conference calls under the Investor Relations section. Please go to the website 15 minutes early to register, download and install any necessary audio software. If you are unable to listen live, a playback of the conference call can be accessed until November 5, 2025 at USPH's website. About U.S. Physical Therapy, Inc. Founded in 1990, U.S. Physical Therapy, Inc. owns and/or manages 768 outpatient physical therapy clinics in 44 states. USPH clinics provide preventative and post-operative care for a variety of orthopedic-related disorders and sports-related injuries, treatment for neurologically-related injuries and rehabilitation of injured workers. USPH also has an industrial injury prevention business which provides onsite services for clients' employees including injury prevention and rehabilitation, performance optimization, post-offer employment testing, functional capacity evaluations, and ergonomic assessments. More information about U.S. Physical Therapy, Inc. is available at The information included on that website is not incorporated into this press release. View source version on Contacts U.S. Physical Therapy, Hendrickson, Chief Financial OfficerEmail: Chendrickson@ Chris Reading, Chief Executive Officer(713) 297-7000 Three Part AdvisorsJoe Noyons(817) 778-8424
Yahoo
26 minutes ago
- Yahoo
The president vows to slash medication cost to an unachievable degree.
President Donald Trump has promised to reduce American drug prices by mathematically impossible figures of up to '1400 percent.' Speaking during a White House event attended by Republican members of Congress and his Cabinet, Trump said he would tackle the long-running issue of high medication costs in the U.S. But Trump did not set any achievable targets for that aim, instead outlining a range of percentages which would yield negative prices, meaning drug companies would have to pay people to take their medications.